Cargando…

Clinical use of azelnidipine in the treatment of hypertension in Chinese patients

BACKGROUND: Hypertension is the most common chronic disease and the calcium channel antagonist is the most popularly used antihypertensive drug in Chinese patients. Azelnidipine is a third generation and long-acting dihydropyridine calcium channel antagonist. A series of research has demonstrated th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Bi-Lian, Zhang, Yin-Zhuang, Luo, Jian-Quan, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348133/ https://www.ncbi.nlm.nih.gov/pubmed/25750535 http://dx.doi.org/10.2147/TCRM.S64288

Ejemplares similares

Inhibitory Effects of Azelnidipine Tablets on Morning Hypertension
por: Kario, Kazuomi, et al.
Publicado: (2013)

Therapeutic Usefulness of a Novel Calcium Channel Blocker Azelnidipine in the Treatment of Hypertension: A Narrative Review
por: Ram, C. Venkata S.
Publicado: (2022)

Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage
por: Kain, Vasundhara, et al.
Publicado: (2010)

Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial
por: Takihata, Masahiro, et al.
Publicado: (2015)

Azelnidipine Exhibits In Vitro and In Vivo Antiviral Effects against Flavivirus Infections by Targeting the Viral RdRp
por: Wang, Zhuang, et al.
Publicado: (2022)

Changes in left ventricular relaxation after azelnidipine treatment in hypertensive patients with diabetes: subanalysis of a prospective single-arm multicentre study
por: Iwakura, Katsuomi, et al.
Publicado: (2014)

Comparison of effects of azelnidipine and trichlormethiazide in combination with olmesartan on blood pressure and metabolic parameters in hypertensive type 2 diabetic patients
por: Yoshii, Hidenori, et al.
Publicado: (2011)

Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial
por: Takami, Takeshi, et al.
Publicado: (2013)

Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)
por: Tawaramoto, Kazuhito, et al.
Publicado: (2015)

Comparison of the physical and thermodynamic stability of amorphous azelnidipine and its coamorphous phase with piperazine
por: Du, Shuang, et al.
Publicado: (2018)

A case of complete atrioventricular block with extremely high blood concentration of azelnidipine
por: Ide, Naohito, et al.
Publicado: (2021)

Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot study
por: Abe, Hiroko, et al.
Publicado: (2012)

Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial [Corrigendum]
Publicado: (2013)

Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study
por: Sugimoto, Ken, et al.
Publicado: (2010)

Potential protective effects of Azelnidipine against cerebral ischemia-reperfusion injury in male rats
por: Fakharaldeen, Zainab, et al.
Publicado: (2022)

Azelnidipine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by targeting MEK1/2
por: Zhao, Lili, et al.
Publicado: (2022)

Azelnidipine Inhibits the Differentiation and Activation of THP-1 Macrophages through the L-Type Calcium Channel
por: Komoda, Hiroshi, et al.
Publicado: (2018)

Azelnidipine may be a valuable drug for chemoprevention of ESCC with high MEK1/2 levels
por: Qian, Haili
Publicado: (2022)

Azelnidipine Inhibits Cultured Rat Aortic Smooth Muscle Cell Death Induced by Cyclic Mechanical Stretch
por: Zhao, Jing, et al.
Publicado: (2014)

Validated Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Azelnidipine and Olmesartan in Their Combined Dosage Form
por: Patel, Jayvadan K, et al.
Publicado: (2014)

Possible Pharmacodynamic Interaction of Azelnidipine with Citicoline Against Ischemic Brain Injury: Behavioral, Biochemical and Histological Alterations
por: Gupta, Varun, et al.
Publicado: (2020)

Effects of Azelnidipine-Carboxymethylcellulose Gel on Healing of Full-Thickness Skin Wounds in Streptozotocin Induced Diabetic Rats
por: Karami, Mohammad Yasin, et al.
Publicado: (2019)

A New Baroreceptor Sensitivity-Restoring Ca-Channel Blocker Diminishes Age-Related Morning Blood Pressure Increase in Hypertensive Patients: Open-Label Monitoring of Azelnidipine Treatment for Hypertension in the Early Morning (At-HOME) Study
por: Kario, Kazuomi, et al.
Publicado: (2010)

Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy
por: Zhou, Xiuman, et al.
Publicado: (2021)

Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis
por: Kain, Vasundhara, et al.
Publicado: (2011)

Azelnidipine, Not Amlodipine, Induces Secretion of Vascular Endothelial Growth Factor From Smooth Muscle Cells and Promotes Endothelial Tube Formation
por: Kawamura, Akira, et al.
Publicado: (2014)

Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
por: Takami, Takeshi, et al.
Publicado: (2011)

Intensified, optimized and standardized management of Chinese patients with hypertension: Comments on “2018 Chinese Guidelines for Prevention and Treatment of Hypertension”
por: Zhang, Wei-Zhong
Publicado: (2019)

Overview of clinical use and side effect profile of valsartan in Chinese hypertensive patients
por: Huang, Qi-Fang, et al.
Publicado: (2013)

Study of Sustained Blood Pressure-Lowering Effect of Azelnidipine Guided by Self-Measured Morning and Evening Home Blood Pressure: Subgroup Analysis of the At-HOME Study
por: Kario, Kazuomi, et al.
Publicado: (2013)

Determinants of hypertension treatment adherence among a Chinese population using the therapeutic adherence scale for hypertensive patients
por: Pan, Jingjing, et al.
Publicado: (2019)

Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
por: He, Shan, et al.
Publicado: (2019)

Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on glucose tolerance and endothelial function - a crossover trial (AGENT)
por: Fukao, Kosuke, et al.
Publicado: (2011)

Trends in the Treatment of Hypertension from the Perspective of Traditional Chinese Medicine
por: Xiong, Xingjiang, et al.
Publicado: (2013)

Chinese Herbal Medicine for the Treatment of Obesity-Related Hypertension
por: Wang, Jie, et al.
Publicado: (2013)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
por: Wang, Chen, et al.
Publicado: (2016)

Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol
por: Fang, Yuan, et al.
Publicado: (2015)

Prevalence of Hypertension in Chinese Cities: A Meta-Analysis of Published Studies
por: Ma, Yu-Quan, et al.
Publicado: (2013)

Reflections on treatment of COVID-19 with traditional Chinese medicine
por: Luo, Hua, et al.
Publicado: (2020)

Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science
por: Xiong, Xingjiang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pja2s515ifg6mbaa3v8ssmrjmm